# Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

> **NCT05149014** · — · COMPLETED · sponsor: **Daiichi Sankyo France** · enrollment: 306 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05149014
- **Lead sponsor:** Daiichi Sankyo France
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05149014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05149014, "Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05149014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*